San Antonio — Rapamycin Holdings, a life sciences business working to commercialize a new formulation of an immunosuppressant as a prostate cancer drug, has changed its name to Emtora Biosciences and hired a new CEO.

Carole Spangler Vaughn is taking over at Emtora for Dan Hargrove, who has spent about 18 months in the chief executive role. Hargrove is also an executive at two clinical research organizations in San Antonio, Cancer Insight and Trauma Insight. He will continue working with Emtora through Cancer Insight, which is running a Phase 1b clinical trial on Emtora’s drug, eRapa. Hargrove replaced co-founder Randy Goldsmith… Read more »